Literature DB >> 17386054

Idiosyncratic adverse reactions to antiepileptic drugs.

Gaetano Zaccara1, Diego Franciotta, Emilio Perucca.   

Abstract

Idiosyncratic drug reactions may be defined as adverse effects that cannot be explained by the known mechanisms of action of the offending agent, do not occur at any dose in most patients, and develop mostly unpredictably in susceptible individuals only. These reactions are generally thought to account for up to 10% of all adverse drug reactions, but their frequency may be higher depending on the definition adopted. Idiosyncratic reactions are a major source of concern because they encompass most life-threatening effects of antiepileptic drugs (AEDs), as well as many other reactions requiring discontinuation of treatment. Based on the underlying mechanisms, idiosyncratic reactions can be differentiated into (1) immune-mediated hypersensitivity reactions, which may range from benign skin rashes to serious conditions such as drug-related rash with eosinophilia and systemic symptoms; (2) reactions involving unusual nonimmune-mediated individual susceptibility, often related to abnormal production or defective detoxification of reactive cytotoxic metabolites (as in valproate-induced liver toxicity); and (3) off-target pharmacology, whereby a drug interacts directly with a system other than that for which it is intended, an example being some types of AED-induced dyskinesias. Although no AED is free from the potential of inducing idiosyncratic reactions, the magnitude of risk and the most common manifestations vary from one drug to another, a consideration that impacts on treatment choices. Serious consequences of idiosyncratic reactions can be minimized by knowledge of risk factors, avoidance of specific AEDs in subpopulations at risk, cautious dose titration, and careful monitoring of clinical response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17386054     DOI: 10.1111/j.1528-1167.2007.01041.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  59 in total

1.  Carbamazepine hypersensitivity: progress toward predicting the unpredictable.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

Review 2.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

3.  Epilepsy: HLA alleles linked to carbamazepine hypersensitivity.

Authors:  Pasquale Striano; Federico Zara
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

Review 4.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

5.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

6.  Early Detection of Human Epileptic Seizures Based on Intracortical Microelectrode Array Signals.

Authors:  Yun S Park; G Rees Cosgrove; Joseph R Madsen; Emad N Eskandar; Leigh R Hochberg; Sydney S Cash; Wilson Truccolo
Journal:  IEEE Trans Biomed Eng       Date:  2019-06-06       Impact factor: 4.538

Review 7.  Contemporary review of drug-induced pancreatitis: A different perspective.

Authors:  Whitney Y Hung; Odaliz Abreu Lanfranco
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

8.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

Review 9.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 10.  The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research.

Authors:  B Alex Merrick
Journal:  Brief Funct Genomic Proteomic       Date:  2008-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.